Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting

EMERYVILLE, Calif.–(BUSINESS WIRE)–Nutcracker Therapeutics presented data on two preclinical candidates — anti-CD47 RNA molecule, NTX-471, and lead candidate, NTX-250.
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks